09:36 AM EDT, 06/10/2025 (MT Newswires) -- MacroGenics ( MGNX ) said Tuesday it signed a royalty purchase deal with Sagard Healthcare Partners in exchange for a capped royalty interest on future worldwide net sales of Zynyz, a PD-1 inhibitor that MacroGenics ( MGNX ) developed originally and licensed to Incyte (INCY).

MacroGenics ( MGNX ) said that under the royalty purchase deal, it received an upfront payment of $70 million for the sale of its royalty rights on Zynyz sales.

The company said it will resume collecting all future royalties following Sagard's receipt of total royalty payments of $140 million.

The company's cash, cash equivalents and marketable securities of $154.1 million as of March 31, combined with the $70 million upfront payment from Sagard, are expected to help support MacroGenics' ( MGNX ) cash runway through H1 of 2027.

MacroGenics ( MGNX ) shares rose 19% in recent Tuesday trading.

Price: 1.95, Change: +0.31, Percent Change: +18.96